

Disclosure of total number of voting rights and number of shares in the capital at December 31st, 2016

Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations.

Total number of shares	11,650,780
Number of real voting rights* (excluding treasury shares)	11,619,953
Theoritical number of voting rights* (including treasury shares**)	11,633,760

^(*) Class B preference shares are non-voting

^(**) pursuant to article 223-11 of the AMF's General Regulations



About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics™ to provide insights into novel therapies and treatment strategies. Our unique solutions, LMS for lesion management and our imaging phenotyping system iBiopsy™, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the

world to bring new treatments to patients in need more precisely, quicker and with an eye on reducing overall care costs. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary in Boston, Median has received the label "Innovative company" by the BPI and is listed on Euronext Paris' Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA-PME SME equity savings plan setup and has received the label Pass French Tech Promotion 2016-2017. More information: www.mediantechnologies.com





Contacts

Median Technologies	Press	Investors
Fredrik Brag, CEO	ALIZE RP	ACTIFIN
+33 4 92 90 65 82	Caroline Carmagnol / Wendy Rigal	Ghislaine Gasparetto
fredrik.brag@mediantechnologies.com	+ 33 1 44 54 36 66	+33 1 56 88 11 11
	median@alizerp.com	ggasparetto@actifin.fr